ClaudiaA.ChiribogaMD
Child Neurology • New York, NYNeuromuscular Medicine
MD, MPH Columbia Presbyterian Medical Center
Overview of Dr. Chiriboga
Dr. Claudia Chiriboga is a Child Neurologist in New York, NY and is affiliated with multiple hospitals in the area, including NewYork-Presbyterian/Columbia University Irving Medical Center and Morgan Stanley Childrens Hospital of NewYork-Presbyterian. She received her medical degree from University of Buenos Aires and has been in practice 38 years. She is one of 24 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center and one of 10 doctors at Morgan Stanley Childrens Hospital of NewYork-Presbyterian who specialize in Child Neurology. She has more than 50 publications and over 500 citings.
Office
180 Fort Washington Avenue
New York, NY 10032
Education & Training
Icahn School of Medicine at Mount SinaiResidency, Pediatrics, 1982 - 1985
University of Buenos AiresClass of 1982
Certifications & Licensure
NJ State Medical License Current
NY State Medical License 1985 - 2026
MD State Medical License 1984 - 1986- American Board of Psychiatry and Neurology Neurology with Special Qualification in Child Neurology
Publications & Presentations
PubMed
- 256 citationsNatural history of infantile-onset spinal muscular atrophy.Stephen J. Kolb, Christopher S. Coffey, Jon W. Yankey, Kristin J. Krosschell, W. David Arnold
Annals of Neurology. 2017-12-01 - 114 citationsOnasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial.Kevin A Strauss, Michelle A Farrar, Francesco Muntoni, Kayoko Saito, Jerry R Mendell
Nature Medicine. 2022-07-01 - 130 citationsOnasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial.Kevin A Strauss, Michelle A Farrar, Francesco Muntoni, Kayoko Saito, Jerry R Mendell
Nature Medicine. 2022-07-01
Press Mentions
- Positive New Data for Genentech’s Evrysdi in Largest Trial Ever Undertaken in Patients with Previously-Treated Spinal Muscular Atrophy (SMA)October 12th, 2022
- New Genentech Data for Evrysdi (Risdiplam) Show Improved Motor Function in Pre-Symptomatic Babies After One Year and Confirm Safety Profile in Previously Treated People with Spinal Muscular Atrophy (SMA)June 11th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
